Recent Updates
Recently added Catalysts

LY2452473

Phase 2

Erectile Dysfunction | Small molecule | Other |Eli Lilly and Company|Last Updated: Jun 14, 2019

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindACTIVE_CONTROLLEDBiomarker
Total Trials2
Total Enrollment434
FDA Designations
No designations recorded
Clinical Trials (2)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01160289A Study of LY900010 in Erectile DysfunctionPHASE2 COMPLETED 410Oct 1, 2010Nov 1, 2011Apr 9, 201936 United States
NCT01401543A Bioavailability Study of LY2452473 and TadalafilPHASE1 COMPLETED 24Jul 1, 2011Sep 1, 2011Jun 14, 20191 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Change From Baseline to 12 Week Endpoint in International Index of Erectile Function (IIEF) Erectile Function (EF) Domain Score
Baseline, Week 12

The IIEF EF domain score was the sum of Questions (Q) 1 to Q5 and Q15 of the IIEF self-reported questionnaire. Q1 to Q5 were rated 0 (low/no EF) to 5 (high EF) and Q15 was rated 1 (no/low confidence) to 5 (high confidence). IIEF EF domain scores ranged from 1 to 30. Higher scores denoted better EF.

Pharmacokinetics: Area Under the Concentration-Time Curve From Time Zero to Infinity [AUC(0-∞)] of LY2452473
Predose up to 96 hours postdose for each of the 4 treatment periods
Pharmacokinetics: Maximum Plasma Concentration (Cmax) of LY2452473
Predose up to 96 hours postdose for each of the 4 treatment periods
Secondary Endpoints
Change From Baseline to 12 Week Endpoint in the Percentage of "Yes" Responses on the Sexual Encounter Profile (SEP) Diary
Baseline, Week 12
Change From Baseline to 12 Week Endpoint in IIEF Domain Scores (Intercourse Satisfaction, Orgasmic Function, Sexual Desire, and Overall Satisfaction)
Baseline, Week 12
Change From Baseline to 12 Week Endpoint in the Percentage of Participants Who Return to "Normal" on the International Index of Erectile Function (IIEF) Scale (EF>25)
Baseline, Week 12
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
1 milligram (mg) LY2452473 + 5 mg tadalafilEXPERIMENTAL -
5 mg LY2452473 + 5 mg tadalafilEXPERIMENTAL -
5 mg LY2452473 + placeboEXPERIMENTAL -
10 mg tadalafil + placeboACTIVE_COMPARATOR -
5 mg tadalafil + placeboACTIVE_COMPARATOR -
LY900010 (particle size #1)EXPERIMENTALSingle combination tablet containing 5 mg tadalafil and 5 mg LY2452473 with a smaller particle size (d90 = 10 microns), administered orally, once only. There will be a washout period of at least 7 days between doses of study drug. d90 is a measurement of the distribution of particle widths such that 90% of the particles have a diameter less than the specified value.
LY900010 (particle size #2)EXPERIMENTALSingle combination tablet containing 5 mg tadalafil and 5 mg LY2452473 with an intermediate particle size (d90 = 25 microns), administered orally, once only. There will be a washout period of at least 7 days between doses of study drug. d90 is a measurement of the distribution of particle widths such that 90% of the particles have a diameter less than the specified value.
LY900010 (particle size #3)EXPERIMENTALSingle combination tablet containing 5 mg tadalafil and 5 mg LY2452473 with a larger particle size (d90 = 40 microns), administered orally, once only. There will be a washout period of at least 7 days between doses of study drug. d90 is a measurement of the distribution of particle widths such that 90% of the particles have a diameter less than the specified value.
Interventions
NameTypeDescription
LY2452473DRUGAdministered orally, once daily for 12 weeks
tadalafilDRUGAdministered orally, once daily for 12 weeks
placebo (tadalafil)DRUGAdministered orally, once daily for 12 weeks
placebo (LY2452473)DRUGAdministered orally, once daily for 12 weeks
LY900010DRUGAdministered orally
Unlock Study Design Details
Eligibility Criteria
Age Range45 Years — 70 Years
SexMALE
Healthy VolunteersNo
Study Sites36

Inclusion Criteria include: * Ambulatory men * History of erectile dysfunction of at least 3 months duration * History of incomplete response to any phosphodiesterase type 5 inhibitor (PDE5i) at the maximum tolerated dose within the label * Anticipate having the same female sexual partner throughou...

Countries:United States
Unlock Eligibility Criteria